Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score

Next Previous
X
Search
Trial Profile

A Randomised Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibuprofen lysinate (Primary)
  • Indications Lung disorders; Patent ductus arteriosus
  • Focus Therapeutic Use
  • Acronyms PDA RCT

    • Most Recent Events

    • 18 Aug 2023 According to ISRCTN Current Controlled Trials record recruitment end date was 1 Jan 2020
    • 15 Oct 2020 Primary endpoint (The primary outcome of the study is chronic lung disease defined as the need for oxygen at 36 weeks corrected age or and/or death before discharge) has not been met according to Results published in the Journal of Pediatrics.
    • 15 Oct 2020 Results published in the Journal of Pediatrics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top